CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The ALIVER Consortium is developing a novel liver dialysis device, DIALIVE, to address liver failure by removing toxins and improving immune function. This device aims to extend patient survival and will undergo clinical trials across Europe to assess its safety and effectiveness in treating acute liver failure.
Liver disease incidence is increasing and about 170K patients die from liver failure each year in Europe.
In liver failure, the accumulation of protein bound toxins and increased susceptibility to infection cause multiorgan failure and death.
Liver transplantation is the only treatment known to prolong the life but is limited by availability of organs. A clinically efficacious ‘liver dialysis device’ is an unmet clinical need.
The ALIVER Consortium has developed and optimised a novel ‘liver dial…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, Ledbury
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Belgium, Landen
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Germany, Rostock
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
